Roman D. Pavlov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Roman D. Pavlov has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Diana E. Kaurova
N.I. Pirogov Russian National Research Medical University
1 shared publication - Dmitrii S. Ivanov
Institute of Bioorganic Chemistry, Russian Academy of Sciences, Miklukho-Maklaya 16/10, 117997 Moscow, Russia
1 shared publication - Dmitry A. Gavrilenko
Tver State Medical University
1 shared publication - Ivan N. Myasnyanko
Laboratory of Medicinal Substances Chemistry, Institute of Translational Medicine, Pirogov Russian National Research Medical University, Ostrovitianova 1, Moscow 117513, Russia
1 shared publication - Mikhail S. Baranov
Laboratory of Medicinal Substances Chemistry, Institute of Translational Medicine, Pirogov Russian National Research Medical University, Ostrovitianova 1, Moscow 117513, Russia
1 shared publication - Nikita S. Popov
Tver State Medical University
1 shared publication
Latest Publications
- Open Access
- 24 November 2025
- Published by Belgorod National Research University in Research Results in Pharmacology
- Vol. 11 (4) , 258-271
Study of the biotransformation of a new sydnonimine derivative with predominant cerebral vasodilatory activity
Introduction: Sydnonimines are a promising group of drugs for development of novel substances with predominant cerebral vasodilatory activity. One of them is experimental compound with laboratory code BBP20233. The mechanism of action of BBP2023 compound is tied to its metabolites. This study aims for identification of biotransformation products of BBP2023 using HPLC-MS/MS method. Materials and Methods: Identification of BBP2023 biotransformation products was performed in male rats and male rabbits after intragastric administration of BBP2023 in form of oil emulsion. Blood samples were collected before and 1 and 8 hours after administration. Urine samples from rats were collected before and 24 hours after administration. Additionally, complete liver isolation was performed in another group of rats to investigate liver’s role in BBP2023 metabolism. Identification of products was performed using HPLC-MS/MS method as well as UHR-TOF method. Results and Discussion: Analysis of rat plasma samples collected 1 hour after administration revealed the presence of parent compound, active metabolite SIN, geranamine and various isomers of OH-derivatives. Analysis of rat urine samples collected 24 hours after administration showed the presence of glucuronic acid conjugates of SIN and parent compound. Similar results were obtained from rabbit plasma samples, although with less variety of hydroxylated derivative isomers. Conclusion: Investigated features of BBP2023 biotransformation require detailed analysis of pharmacokinetics for both BBP2023 and its metabolites to determine their role in therapeutic effect and possible adverse effects.
- 24 November 2025
- Published by Belgorod National Research University in Research Results in Pharmacology
- Vol. 11 (4) , 258-271
Open AccessStudy of the biotransformation of a new sydnonimine derivative with predominant cerebral vasodilatory activity
Introduction: Sydnonimines are a promising group of drugs for development of novel substances with predominant cerebral vasodilatory activity. One of them is experimental compound with laboratory code BBP20233. The mechanism of action of BBP2023 compound is tied to its metabolites. This study aims for identification of biotransformation products of BBP2023 using HPLC-MS/MS method. Materials and Methods: Identification of BBP2023 biotransformation products was performed in male rats and male rabbits after intragastric administration of BBP2023 in form of oil emulsion. Blood samples were collected before and 1 and 8 hours after administration. Urine samples from rats were collected before and 24 hours after administration. Additionally, complete liver isolation was performed in another group of rats to investigate liver’s role in BBP2023 metabolism. Identification of products was performed using HPLC-MS/MS method as well as UHR-TOF method. Results and Discussion: Analysis of rat plasma samples collected 1 hour after administration revealed the presence of parent compound, active metabolite SIN, geranamine and various isomers of OH-derivatives. Analysis of rat urine samples collected 24 hours after administration showed the presence of glucuronic acid conjugates of SIN and parent compound. Similar results were obtained from rabbit plasma samples, although with less variety of hydroxylated derivative isomers. Conclusion: Investigated features of BBP2023 biotransformation require detailed analysis of pharmacokinetics for both BBP2023 and its metabolites to determine their role in therapeutic effect and possible adverse effects.